MDS-PAS Congress 2026 Session Evaluation - Session 1102

  • MDS-PAS Congress 2026 Session 1102 Evaluation Form

  • Plenary Session 1102

    Novel Genetic Therapies for Movement Disorders

    February 13, 2026

    10:15 - 12:00

  • Learning Objectives:

    1. Evaluate recent preclinical studies and clinical trial data for novel genetic therapies for Parkinson's disease
    2. Evaluate recent preclinical studies and clinical trial data for novel genetic therapies for Huntington's disease
    3. Evaluate recent preclinical studies and clinical trial data for novel genetic therapies for rare metabolic disorders

  • Session Evaluation

  • The session met its learning objectives
  • The content is relevant to my professional and / or scientific interests.
  • The quality of the education process (method of presentation and information provided) was satisfactory and appropriate.
  • The information provided will enhance my care of patients with Movement Disorders and / or advance my scientific understanding of Movement Disorders.
  • The overall session organization was satisfactory and appropriate.
  • I would recommend this session to a colleague.

  • Faculty Assessment

  • Matthew Farrer

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

  • Tiago Mestre

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.

  • Jennifer Friedman

  • This speaker was able to effectively communicate the content of their presentation
  • The information was presented without commercial bias. The speaker did not discuss a single branded commercial product or service.
  • The following category best describes your current major professional activity (choose one):

  • Should be Empty: